Medical devices; exception from general requirements for informed consent. Final rule

Area of Science:

• Regulatory Science
• Medical Device Regulation
• Public Health Preparedness

Background:

• In vitro diagnostic devices are crucial for identifying hazardous agents.
• Informed consent requirements can delay critical diagnostic procedures during emergencies.
• The Food and Drug Administration (FDA) previously issued an interim final rule (IFR) to address this.

Purpose of the Study:

• To confirm and finalize the IFR regarding exceptions to informed consent for specific diagnostic device use.
• To ensure timely access to investigational in vitro diagnostic devices during public health emergencies involving chemical, biological, radiological, or nuclear (CBRN) agents.
• To enhance the regulatory framework for medical devices used in critical situations.

Main Methods:

• The FDA reviewed public comments on the interim final rule.
• A final regulation was issued, confirming the IFR with a modification.
• The modification includes an additional documentation submission requirement for investigators.

Main Results:

• The final rule confirms the exception to general informed consent requirements for using investigational in vitro diagnostic devices in specific CBRN agent identification scenarios.
• A new requirement mandates that investigators submit required documentation to the FDA, in addition to the Institutional Review Board (IRB).

Conclusions:

• The finalized regulation facilitates the rapid deployment of essential diagnostic tools during public health crises.
• This regulatory adjustment balances the need for timely medical intervention with appropriate oversight.
• The updated process aims to improve patient outcomes following exposure to CBRN agents.